Odyssey Therapeutics, Inc.
ODTX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$590.4M
Close$
$-1.04
105.3% downside
Current Fair Value
105.3% downsideOvervalued by 105.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $590.40 Million |
|---|---|
| Enterprise Value | $533.20 Million |
| Earnings per Share | $-5.39 |
| Beta | 1.43 |
| Outstanding Shares | 30,277,051 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -7.66 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | 1.5 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 4, 2026
EPS Estimate
$-1.13
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.03%▼ 115.55% |
|---|---|
| Total Invested | $211,090▼ 99.97% |
| Investors Holding | 2▼ 58.00% |
About Odyssey Therapeutics, Inc.
100 employees
CEO: Gary D. Glick
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an ...